We still expect our revenue for the full year to be between $75,000,000 $85,000,000 which includes $55,000,000 to $65,000,000 in noncash royalties and $20,000,000 to $25,000,000 in product sales. For the second half of the year, we expect the remaining revenue to be weighted more heavily towards the Q4. R and D expense for the 2nd quarter of 2024 was $29,700,000 and we still anticipate full year R and D expense to range between $120,000,000 $130,000,000 G and A expense for the Q2 of 2024 was 20,500,000 dollars We continue to expect G and A expense for the full year to be between $70,000,000 $75,000,000 Lastly, our 2024 non cash interest expense remains unchanged and is expected to be between $20,000,000 25,000,000 dollars In Q2, we recorded $13,300,000 in non cash impairment charges for our real estate obligations due to the continuous decline of the San Francisco Life Sciences and Office Real Estate markets. Our net loss for the Q2 of 2024 was $52,400,000 or $0.25 basic and diluted loss per share. Excluding the $13,300,000 in non cash impairment charges, net loss on a non GAAP basis was $39,100,000 or $0.19 basic and diluted loss per share.